QQQ   269.33 (-2.55%)
AAPL   109.22 (-5.29%)
MSFT   200.98 (-1.83%)
FB   263.70 (-6.10%)
GOOGL   1,621.27 (+4.14%)
AMZN   3,066.78 (-4.49%)
TSLA   388.41 (-5.46%)
NVDA   498.08 (-4.39%)
BABA   302.19 (-3.32%)
CGC   18.42 (-1.92%)
GE   7.38 (+0.14%)
MU   49.88 (-1.19%)
AMD   75.04 (-3.82%)
T   26.86 (+0.37%)
F   7.71 (-2.41%)
ACB   3.95 (-3.42%)
GILD   57.67 (-1.47%)
NIO   30.51 (-4.63%)
NFLX   478.50 (-5.10%)
BA   143.32 (-3.35%)
DIS   120.01 (-1.26%)
QQQ   269.33 (-2.55%)
AAPL   109.22 (-5.29%)
MSFT   200.98 (-1.83%)
FB   263.70 (-6.10%)
GOOGL   1,621.27 (+4.14%)
AMZN   3,066.78 (-4.49%)
TSLA   388.41 (-5.46%)
NVDA   498.08 (-4.39%)
BABA   302.19 (-3.32%)
CGC   18.42 (-1.92%)
GE   7.38 (+0.14%)
MU   49.88 (-1.19%)
AMD   75.04 (-3.82%)
T   26.86 (+0.37%)
F   7.71 (-2.41%)
ACB   3.95 (-3.42%)
GILD   57.67 (-1.47%)
NIO   30.51 (-4.63%)
NFLX   478.50 (-5.10%)
BA   143.32 (-3.35%)
DIS   120.01 (-1.26%)
QQQ   269.33 (-2.55%)
AAPL   109.22 (-5.29%)
MSFT   200.98 (-1.83%)
FB   263.70 (-6.10%)
GOOGL   1,621.27 (+4.14%)
AMZN   3,066.78 (-4.49%)
TSLA   388.41 (-5.46%)
NVDA   498.08 (-4.39%)
BABA   302.19 (-3.32%)
CGC   18.42 (-1.92%)
GE   7.38 (+0.14%)
MU   49.88 (-1.19%)
AMD   75.04 (-3.82%)
T   26.86 (+0.37%)
F   7.71 (-2.41%)
ACB   3.95 (-3.42%)
GILD   57.67 (-1.47%)
NIO   30.51 (-4.63%)
NFLX   478.50 (-5.10%)
BA   143.32 (-3.35%)
DIS   120.01 (-1.26%)
QQQ   269.33 (-2.55%)
AAPL   109.22 (-5.29%)
MSFT   200.98 (-1.83%)
FB   263.70 (-6.10%)
GOOGL   1,621.27 (+4.14%)
AMZN   3,066.78 (-4.49%)
TSLA   388.41 (-5.46%)
NVDA   498.08 (-4.39%)
BABA   302.19 (-3.32%)
CGC   18.42 (-1.92%)
GE   7.38 (+0.14%)
MU   49.88 (-1.19%)
AMD   75.04 (-3.82%)
T   26.86 (+0.37%)
F   7.71 (-2.41%)
ACB   3.95 (-3.42%)
GILD   57.67 (-1.47%)
NIO   30.51 (-4.63%)
NFLX   478.50 (-5.10%)
BA   143.32 (-3.35%)
DIS   120.01 (-1.26%)
Log in
NASDAQ:GH

Guardant Health Stock Forecast, Price & News

$107.04
-2.64 (-2.41 %)
(As of 10/30/2020 11:55 AM ET)
Add
Compare
Today's Range
$105.68
Now: $107.04▼
$109.55
50-Day Range
$95.01
MA: $105.15▼
$111.80
52-Week Range
$55.90
Now: $107.04▼
$114.33
Volume3,049 shs
Average Volume1.04 million shs
Market Capitalization$10.64 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.51
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. The company has collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.17 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GH
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.guardanthealth.com
Phone855-698-8887
Employees622

Debt

Debt-to-Equity RatioN/A
Current Ratio14.42
Quick Ratio14.13

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$214.38 million
Price / Sales49.64
Cash FlowN/A
Price / Cash FlowN/A
Book Value$8.50 per share
Price / Book12.59

Profitability

EPS (Most Recent Fiscal Year)($0.84)
Net Income$-75,650,000.00
Net Margins-45.53%
Return on Equity-13.35%
Return on Assets-11.34%

Miscellaneous

Outstanding Shares99,424,000
Market Cap$10.64 billion
Next Earnings Date11/5/2020 (Confirmed)
OptionableNot Optionable
$107.04
-2.64 (-2.41 %)
(As of 10/30/2020 11:55 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GH News and Ratings via Email

Sign-up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Guardant Health (NASDAQ:GH) Frequently Asked Questions

How has Guardant Health's stock been impacted by Coronavirus (COVID-19)?

Guardant Health's stock was trading at $62.95 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GH stock has increased by 72.5% and is now trading at $108.60.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Guardant Health?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Guardant Health.

When is Guardant Health's next earnings date?

Guardant Health is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Guardant Health.

How can I listen to Guardant Health's earnings call?

Guardant Health will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.17. The firm had revenue of $66.30 million for the quarter, compared to the consensus estimate of $59.18 million. Guardant Health had a negative return on equity of 13.35% and a negative net margin of 45.53%. The company's revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.13) earnings per share.
View Guardant Health's earnings history.

What price target have analysts set for GH?

7 brokers have issued twelve-month target prices for Guardant Health's stock. Their forecasts range from $100.00 to $130.00. On average, they expect Guardant Health's share price to reach $113.00 in the next twelve months. This suggests a possible upside of 4.1% from the stock's current price.
View analysts' price targets for Guardant Health.

Are investors shorting Guardant Health?

Guardant Health saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 2,210,000 shares, a decrease of 12.3% from the August 31st total of 2,520,000 shares. Based on an average trading volume of 836,900 shares, the short-interest ratio is currently 2.6 days. Currently, 2.8% of the shares of the stock are sold short.
View Guardant Health's Short Interest.

Who are some of Guardant Health's key competitors?

Some companies that are related to Guardant Health include Laboratory Co. of America (LH), Quest Diagnostics (DGX), InVitae (NVTA), Natera (NTRA), ELEKTA AB/ADR (EKTAY), Burning Rock Biotech (BNR), CareDx (CDNA), Veracyte (VCYT), Castle Biosciences (CSTL), Genetron (GTH), Personalis (PSNL), RadNet (RDNT), Fulgent Genetics (FLGT), Renalytix AI (RNLX) and Progenity (PROG).
View all competitors.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), The Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

Who are Guardant Health's key executives?

Guardant Health's management team includes the following people:
  • Mr. AmirAli Talasaz, Pres, COO & Chairman (Age 40, Pay $914.91k)
  • Dr. Helmy Eltoukhy Ph.D., Co-Founder, CEO & Director (Age 41, Pay $914.91k)
  • Mr. Derek A. Bertocci, Chief Financial Officer (Age 66, Pay $614.06k)
  • Dr. Richard B. Lanman, Advisor (Age 65, Pay $540.15k)
  • Mr. Kumud Kalia, Chief Information Officer
  • Mr. John G. Saia, Sr. VP, Gen. Counsel & Corp. Sec. (Age 47)
  • Ms. Amelia Merrill, VP of People
  • Mr. Mark Jacobstein, Chief User Engagement Officer
  • Mr. Andy Ament, Sr. VP of Operations
  • Mr. Daniel Simon, Sr. VP of Biopharma Bus. Devel.

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Railway Pension Investments Ltd (0.31%), Westwood Management Corp IL (0.29%), Chicago Capital LLC (0.25%), Rhenman & Partners Asset Management AB (0.24%), Candriam Luxembourg S.C.A. (0.09%) and Carnegie Capital Asset Management LLC (0.09%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank.
View institutional ownership trends for Guardant Health.

Which institutional investors are selling Guardant Health stock?

GH stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Arden Trust Co, State of New Jersey Common Pension Fund D, CENTRAL TRUST Co, and Asset Management Corp IL ADV. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, and Stanley J Meresman.
View insider buying and selling activity for Guardant Health.

Which institutional investors are buying Guardant Health stock?

GH stock was acquired by a variety of institutional investors in the last quarter, including Railway Pension Investments Ltd, Rhenman & Partners Asset Management AB, DekaBank Deutsche Girozentrale, Candriam Luxembourg S.C.A., CWM LLC, Carnegie Capital Asset Management LLC, Cambridge Investment Research Advisors Inc., and Icon Wealth Partners LLC.
View insider buying and selling activity for Guardant Health.

How do I buy shares of Guardant Health?

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $108.60.

How big of a company is Guardant Health?

Guardant Health has a market capitalization of $10.80 billion and generates $214.38 million in revenue each year. The company earns $-75,650,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Guardant Health employs 622 workers across the globe.

What is Guardant Health's official website?

The official website for Guardant Health is www.guardanthealth.com.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887.

This page was last updated on 10/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.